Update shared on 04 Sep 2025
With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677.
What's in the News
- Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.
- The company has been selected for a tax incentive award by Massachusetts Life Sciences Center to support its expansion, which will create new jobs in the region.
- The Board of Cipla is scheduled to meet to consider and approve unaudited financial results for the quarter ended June 30, 2025.
Valuation Changes
Summary of Valuation Changes for Cipla
- The Consensus Analyst Price Target remained effectively unchanged, at ₹1677.
- The Consensus Revenue Growth forecasts for Cipla remained effectively unchanged, at 8.4% per annum.
- The Net Profit Margin for Cipla remained effectively unchanged, at 15.92%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.